Conditions: Carcinoma, Renal Cell; Head and Neck Neoplasm; Skin Neoplasms; Microsatellite Instability; Penile Neoplasms
Intervention: Drug: Nivolumab
Sponsors: UNICANCER; National Cancer Institute, France; Ligue contre le cancer, France; Bristol-Myers Squibb
Not yet recruiting - verified January 2017
Next Steps in Immuno-Oncology: Enhancing Antitumor Effects - Is dual immune checkpoint blockade synergistic and safe? Find the latest research here. *Annals of Oncology* from Uncategorized via xlomafota13 on Inoreade...